Proven clinical trial efficacy

Radiographic data

Many HUMIRA-treated patients experienced significant inhibition of radiographic progression at week 48 vs week 24 of placebo.1,2

Signs and symptoms

Most HUMIRA-treated patients saw significant improvement in signs and symptoms at week 12 vs placebo.1,3

HAQ-DI scores

Many HUMIRA-treated patients saw significant improvement in physical function at week 12 vs placebo.1

Clinically studied safety data

clinically studied safety profile in PsA patients

Well-studied safety profile in clinical trials.1,5,6

Every-other-week dosing

Every-other-week dosing schedule starting one week after initial dose.

HUMIRA Citrate-free

No citrate buffers, thinner needle, less pain immediately following injection compared with the HUMIRA 40 mg/0.8 mL presentation.8†§

HUMIRA Citrate-free is available to all indicated patients in the United States. HUMIRA Citrate-free features the same safety and efficacy profile of HUMIRA you've come to count on.
§Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.